Author Archives: David George

Servier and the Autonomous University of Barcelona collaborate to accelerate research into Parkinson’s Disease

Paris (France) and Barcelona (Spain), June, 30 2020 – Servier, an international independent pharmaceutical company, and the Autonomous University of Barcelona (UAB), have signed a partnership agreement to speed up research into Parkinson’s disease, using a new method for small-molecule screening developed by Prof Salvador Ventura, PhD, group leader at the Institute of Biotechnology and […]

Servier completes the acquisition of Symphogen

Symphogen, a Danish biotechnology company specializing in the research and development of monoclonal antibodies, becomes Servier’s center of excellence for antibodies, strengthening the Group’s pipeline in various therapeutic areas, including oncology. Symphogen, now a subsidiary of Servier, keep its operational autonomy and continue to rely on its experienced employees. As part of the acquisition, Christophe […]

Golden Ticket 2020 Awarded To Rgenta Therapeutics

Servier has awarded the 2020 Servier Golden Ticket at LabCentral to Rgenta Therapeutics, a new biotech company focusing on developing RNA-targeting medicines for difficult to treat disease-relevant targets. Awarded since 2017 by Servier, this prize aims to support, for one year, a research project of a start-up corresponding to one of the Group’s therapeutic areas. The […]

Servier Australia & BioCurate strike an agreement to collaborate and accelerate discoveries of new therapeutics and drugs

Paris & Melbourne, July 16th 2019 – Servier Australia, the subsidiary of Servier Group, an international pharmaceutical company, and BioCurate, a joint venture company of Monash University and The University of Melbourne with support from the Victorian State Government, have struck an agreement to share commercial and scientific expertise with the aim of accelerating the […]

Servier cuts ribbon on new Boston Headquarters

French Pharmaceutical Company with Large Global Presence  Finally Puts Down Roots in U.S. Oncology is Significant Focus BOSTON, Mass. (May 9, 2019) Servier Pharmaceuticals, a U.S. subsidiary of the global French pharmaceutical company Servier Group, today officially opened its American headquarters, expanding its global footprint and taking yet another step toward becoming one of the […]

Servier’s latest annual report now published

The 2017-2018 Annual Report is now available. It features the main strategic goals and the highlights of the year: the Group’s new business presence in the US, the setting up of a production unit for biological drugs, the launching of our patient-centred strategy… It also looks ahead to the Servier of tomorrow, as envisioned by […]